Immunogenicity of Human Mesenchymal Stem Cells in HLA-Class I-Restricted T-Cell Responses Against Viral or Tumor-Associated Antigens
Open Access
- 21 February 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 26 (5) , 1275-1287
- https://doi.org/10.1634/stemcells.2007-0878
Abstract
Human mesenchymal stem cells (MSC) are immunosuppressive and poorly immunogenic but may act as antigen-presenting cells (APC) for CD4+ T-cell responses; here we have investigated their ability to serve as APC for in vitro CD8+ T-cell responses. MSC pulsed with peptides from viral antigens evoked interferon (IFN)-γ and Granzyme B secretion in specific cytotoxic T lymphocytes (CTL) and were lysed, although with low efficiency. MSC transfected with tumor mRNA or infected with a viral vector carrying the Hepatitis C virus NS3Ag gene induced cytokine release but were not killed by specific CTL, even following pretreatment with IFN-γ. To investigate the mechanisms involved in MSC resistance to CTL-mediated lysis, we analyzed expression of human leukocyte antigen (HLA) class I-related antigen-processing machinery (APM) components and of immunosuppressive HLA-G molecules in MSC. The LMP7, LMP10, and ERp57 components were not expressed and the MB-1 and zeta molecules were downregulated in MSC either unmanipulated or pretreated with IFN-γ. Surface HLA-G was constitutively expressed on MSC but was not involved in their protection from CTL-mediated lysis. MSC supernatants containing soluble HLA-G (sHLA-G) inhibited CTL-mediated lysis, whereas those lacking sHLA-G did not. The role of sHLA-G in such inhibition was unambiguously demonstrated by partial restoration of lysis following sHLA-G depletion from MSC supernatants. In conclusion, human MSC can process and present HLA class I-restricted viral or tumor antigens to specific CTL with a limited efficiency, likely because of some defects in APM components. However, they are protected from CTL-mediated lysis through a mechanism that is partly sHLA-G-dependent.Disclosure of potential conflicts of interest is found at the end of this article.Keywords
This publication has 77 references indexed in Scilit:
- Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G ReleaseCancer Research, 2007
- Mesenchymal stromal cellsCurrent Opinion in Hematology, 2006
- Tumor mRNA-Transfected Dendritic Cells Stimulate the Generation of CTL That Recognize Neuroblastoma-Associated Antigens, Kill Tumor Cells: Immunotherapeutic ImplicationsNeoplasia, 2006
- Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative settingBlood, 2006
- Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcomaThe Journal of Experimental Medicine, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotectionExpert Opinion on Biological Therapy, 2005
- Report of the Wet Workshop for Quantification of Soluble HLA-G in Essen, 2004Human Immunology, 2005
- β2-μ-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with β2-μ-associated HLA class I heavy chain levels and HLA phenotypeTissue Antigens, 1999
- Phenotypic and Functional Separation of Memory and Effector Human CD8+ T CellsThe Journal of Experimental Medicine, 1997